Nasdaq GlobeNewswire

XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer

Del

AUSTIN, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today enrollment of the first patient into a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator, Medical Oncology lead for the Gastrointestinal Disease Research Group and Co-Director of Pancreas Oncology at Cedars-Sinai. A total of 16 patients are expected to be enrolled in the study.

Dr. Hendifar commented, "We are excited to enroll our first patient in this novel combinatorial therapy for the treatment of advanced pancreatic cancer and cachexia. This is the first attempt to add an anti-inflammatory therapy to standard chemotherapy in an effort to improve the performance, quality of life, and survival in patients with this disease."

The study will also assess overall and progression free survival as well as evaluate the relationship between treatment tolerance and patient functional status. Various secondary measures, including changes in lean body mass, weight stability and levels of systemic inflammation will also be monitored. Onivyde will be given intravenously with MABp1 and 5-fluorouraci l /folinic acid every two weeks until disease progression.

The prognosis for advanced pancreatic cancer remains poor despite decades of studies [1].  The 5-year survival has remained close to 5%, unchanged despite improvements in chemotherapeutics, surgical outcomes, and diagnostic techniques [1, 2].  Other than multi-agent cytotoxic therapy there have been no treatment advances for pancreatic cancer or its associated cachexia.

MABp1 was found to improve clusters of symptoms that included reduced pain, fatigue, improved appetite and increased lean body mass in advanced cancer patients. Patients that had these improvements were found to have less tumor progression, substantial reduced serious adverse events related to disease, and about a three-fold improvement in survival [3].

About True Human(TM) Therapeutic Antibodies
XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human(TM) proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930

  1. Li, D., et al.,  Pancreatic cancer.  Lancet, 2004.  363 (9414): p. 1049-57.
  2. Panagiotarakou, M., et al.,  Use of supportive care for symptom management in pancreatic cancer: application of clinical research to patient care.  Jop, 2012.  13 (4): p. 342-4.
  3. Hickish T., et al.,  MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol. 2017 Feb;18(2):192-201.



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Airtel and Cisco Team to Improve Mobile User Experience25.2.2018 12:00Pressemelding

Utilizing Cisco's Self-Optimizing Network solutions to manage and support the massive growth in data and voice traffic BARCELONA, Spain, Feb. 25, 2018 (GLOBE NEWSWIRE) -- Mobile World Congress - With mobile data consumption surpassing usage of the U.S. and China in 20171, mobile service providers in India are working to enhance their network infrastructure to manage and support the growth surge and ensure quality of customer experience. Bharti Airtel (Airtel), India's largest telecommunications services provider, and Cisco have joined forces to improve customer experience by taking their SON collaboration to next level. SON is now carrying out optimization based on customer experience and predictive analytics apart from the traditional approach of responding to network degradations. SON self-healing applications have been enriched for taking proactive actions in near real time, using predictive machine learning and interworking of SON with NOC tools, PM analytics & customer experience

Cisco Spearheads Multi-Vendor Open vRAN Ecosystem Initiative For Mobile Networks25.2.2018 12:00Pressemelding

First ecosystem of its kind brings together innovators including Reliance Jio, Altiostar, Aricent, Intel, Mavenir, Phazr, Red Hat, and Tech Mahindra BARCELONA, Spain, Feb. 25, 2018 (GLOBE NEWSWIRE) -- Mobile World Congress - Mobile network operators are facing strong pressures to evolve their businesses and operations for profitable growth and differentiation. Explosive demand for bandwidth persists, while ARPU pressures mount due to competition and limited service innovation. Addressing these challenges requires industry innovation focused on delivering new revenue-generating services based on a more flexible and agile service delivery environment, while reducing Capex and Opex. Innovations such as network function virtualization have laid the groundwork for a new fundamental architecture to emerge. While many functions of a mobile network are being virtualized, including the Evolved Packet Core (EPC), IP Multimedia Subsystems (IMS), the Gateway Internet LAN (Gi-LAN) and data transpor

TIM and Cisco Join Forces To Increase The IT Security Of Italian Companies25.2.2018 12:00Pressemelding

TIM Safe Web, the new security service developed in collaboration with Cisco and integrated into the TIM network, going live in March BARCELONA, Spain, Feb. 25, 2018 (GLOBE NEWSWIRE) -- Mobile World Congress - Starting from March, TIM, the leading provider of mobile and fixed telecommunication services in Italy, in partnership with Cisco will offer "TIM Safe WEB", a highly secure platform service, integrated in the TIM network, able to safeguard small business users from malware, such as ramsomware, phishing, and other malicious cybersecurity activities. TIM Safe Web combines TIM's unique technologies and information with the capabilities of the Cisco Umbrella cloud-based security platform, which leverages a constantly updated global database of threat intelligence. This "over-the-network" service enhancement will be provided to about 600.000 TIM Business customers in order to improve both security and quality of service starting from small business market that is very exposed to cyber

Cisco Launches New '5G Now' Portfolio for Service Providers Taking Action Today25.2.2018 12:00Pressemelding

More than 20 global service provider and mobile operator customers worldwide are advancing their 5G action plans with Cisco BARCELONA, Spain, Feb. 25, 2018 (GLOBE NEWSWIRE) -- Mobile World Congress - Continuing on its path to disrupt the industry by redefining the network, Cisco announced today its '5G Now' portfolio for service providers ready to go full throttle on their 5G roadmap. 5G services promise to offer emerging new services at significantly faster speeds, expanded capacity and stronger coverage to accommodate the more than 27 billion connected devices1 expected on service provider networks by 2021. Beginning 2020, 5G connections will grow more than a thousand percent from 2.3 million in 2020 to over 25 million in 20212. At Mobile World Congress this week, many technology vendors are focused on the spectrum advantages, radio equipment and architecture to support 5G services. Cisco is committed to showing service providers and mobile operators why 5G is important to plan for,

Cisco and TIM: Together to Accelerate Italy's Digitization25.2.2018 12:00Pressemelding

BARCELONA, Spain, Feb. 25, 2018 (GLOBE NEWSWIRE) -- Mobile World Congress - Cisco and TIM, the leading service provider in Italy, announced a major agreement aimed at accelerating Italy's digitization today at Mobile World Congress. The two companies are engaged in developing a joint business and innovation program. They will leverage their unique competences and technologies, to create next generation solutions and services focused in particular on Cybersecurity, Internet of Things, Industry 4.0, Smart Cities and 5G. This Memorandum of Understanding (MOU) has been signed in the framework of Digitaliani, the three-year investment plan launched by Cisco in January 2016, whose objectives are well aligned with TIM own digitization program. The partnership is based on three pillars. Sharing competences and solutions for the digital transformation of companies, public sector and services targeted to citizens A common effort to develop a partner ecosystem able to leverage the new opportuniti

Valero to Purchase SemLogistics Milford Haven Fuel Storage Facility23.2.2018 22:15Pressemelding

LONDON, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Valero Logistics UK Ltd, a subsidiary of Valero Energy Corporation (NYSE:VLO), and SemGroup Europe Holding L.L.C., a SemGroup Corporation company, have today signed an agreement for the purchase of SemLogistics Milford Haven fuel storage facility on the west coast of Wales. Situated across the Haven from Valero's refinery at Pembroke, the facility is one of the largest petroleum products storage facility in the United Kingdom (UK) with 8.5 million barrels of capacity for storing gasoline, gasoline blendstocks, naphtha, jet fuel, gas oil, diesel, and crude oil. Over 67 percent of the storage capacity is multiproduct or dual purpose, giving Valero the flexibility to meet customers' demands in the UK and throughout Northwest Europe. Additionally, Milford Haven will continue to operate as a third-party storage facility, offering storage options for third party customers across the European petroleum markets. "This facility complements our Pembroke

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom